Unique ID issued by UMIN | UMIN000028404 |
---|---|
Receipt number | R000032511 |
Scientific Title | Psychological stress-reducing effect by single or continual ingestion of gamma-aminobutyric acid (GABA): a systematic review with meta-analysis. |
Date of disclosure of the study information | 2018/12/31 |
Last modified on | 2023/01/11 10:43:58 |
Psychological stress-reducing effect by single or continual ingestion of gamma-aminobutyric acid (GABA): a systematic review with meta-analysis.
Psychological stress-reducing effect by single or continual ingestion of gamma-aminobutyric acid (GABA)
Psychological stress-reducing effect by single or continual ingestion of gamma-aminobutyric acid (GABA): a systematic review with meta-analysis.
Psychological stress-reducing effect by single or continual ingestion of gamma-aminobutyric acid (GABA)
Japan |
This study will be restricted to all original articles of healthy adults (people not suffering from any diseases). We will exclude minors, pregnant women, those planning a pregnancy, and lactating women.
Adult |
Others
NO
The objective of this review is to assess psychological stress-reducing effect by single or continual ingestion of GABA.
Efficacy
Others
Others
Not applicable
We will evaluate the effect by single or continual ingestion of GABA on brain waves, heart rate variability (HRV) and salivary markers (cortisol, alpha-amylase, chromogranin A (CgA)) reported as assessment indices of psychological stress.
We will evaluate the effect by single or continual ingestion of GABA on biochemical markers (body surface temperature and reaction of the eye pupil towards a flash of light, et al.), physiological markers (blood markers (cortisol and adrenocorticotropic hormone (ACTH), et al.) and salivary markers, et al.) and subjective assessment (the Profile of Mood States (POMS) and visual analogue scale (VAS), et al.) reported as assessment indices of psychological stress.
Others,meta-analysis etc
20 | years-old | <= |
Not applicable |
Male and Female
(Study design)
We will include randomized controlled trials (RCT), quasi randomized controlled trials (qRCT), non-randomized controlled trials (nonRCT), crossover trials, cohort studies, and case-control studies.
We will include scientific papers and reports which give us enough research details.
(A) SR on single ingestion of GABA
(PICO)
Participant:
We will include people not suffering from any diseases. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women.
Intervention:
We define a single ingestion of test food containing GABA as an intervention.
Comparison:
We define ingestion of test food not containing GABA or maintaining daily life as controls.
Outcome measurement:
We will evaluate brain waves, HRV and salivary markers (cortisol, alpha-amylase, CgA) as assessment indices of psychological stress.
The secondary outcomes are biochemical markers (body surface temperature and reaction of the eye pupil towards a flash of light, et al.), physiological markers (blood markers (cortisol and ACTH, et al.) and salivary markers, et al.) and subjective assessment (POMS and VAS, et al.).
(B) SR on continual ingestion of GABA
(PI(E)CO)
Participant:
Same as (A)
Intervention:
We define continual ingestion of test food containing GABA as an intervention.
Comparison 1:
Same as (A)
Exposure:
We define continual ingestion of food containing GABA as an exposure.
Comparison 2:
We define eating no food containing GABA as non-exposure. If subgroup analysis of GABA intake amount has been conducted in a study, we define the least intake group as a non-exposure group.
Outcome measurement:
Same as (A)
(Language)
Eligibility is not restricted by language.
We will exclude cross-sectional studies because it will be difficult to interpret causal relationships between exposure and outcome. We will also exclude proceedings and unpublished studies.
100
1st name | Koichi |
Middle name | |
Last name | Aizawa |
Kagome Co., Ltd.
Innovation Division
329-2762
17 Nishitomiyama, Nasushiobara-shi, Tochigi
0287-36-2935
g167_0@kagome.co.jp
1st name | Koichi |
Middle name | |
Last name | Aizawa |
Kagome Co., Ltd.
Innovation Division
329-2762
17 Nishitomiyama, Nasushiobara-shi, Tochigi
0287-36-2935
g167_0@kagome.co.jp
Kagome Co., Ltd.
None
Self funding
Review Team
Professor Hiroharu Kamioka, Department of Ecological Symbiotic Science, Tokyo University of Agriculture
Dr. Takahiro Yoshizaki, Department of Food and Nutritional Sciences, Toyo University
Ms. Mari Makishi, NARASHINO Media Center for Research & Education, Media Net Center, TOHO University.
Mr. Takuro Inoue, Innovation Division,
Kagome Co., Ltd.
Ms. Tomoka Okame, Innovation Division, Kagome Co., Ltd.
Ms. Ayaka Tsutsumi, Innovation Division, Kagome Co., Ltd.
-
Nihonbashi-Hamacyo F Tower 3-21-1, Nihonbashi-Hmacyo, Chuo-ku, Tokyo
03-5623-8501
toshika_okuni@kagome.co.jp
NO
2018 | Year | 12 | Month | 31 | Day |
Published
244
Main results already published
2017 | Year | 07 | Month | 27 | Day |
2017 | Year | 07 | Month | 27 | Day |
2017 | Year | 07 | Month | 28 | Day |
2019 | Year | 06 | Month | 07 | Day |
2020 | Year | 12 | Month | 31 | Day |
(Searches)
A hospital librarian (e.g., MM) will search 19 databases for studies from the beginning of each database to the search date.
(Data extraction)
Two authors (e.g., TI and TO, or TI and AT) will independently apply all criteria to the full text of articles that have passed the first eligibility screening. Then they will independently extract data from the included studies and cross-check the data.
(Risk of bias assessment)
In order to ensure that variation is not caused by systematic errors in the study or execution, two authors (e.g., TI and TO, or TI and AT) will independently assess the quality of articles. A full quality appraisal of these papers will be made using modified check list (12 items) of Cochrane Handbook for interventional trials, or modified check list (5 items) of GRADE Handbook for observational trials. We will exclude papers with high risk of bias.
Disagreement and uncertainties will be resolved by discussion with another author (e.g., KA). In addition, we will calculate agreement rate and kappa coefficient.
(Inconsistency evaluation)
We will evaluate inconsistency of evidence according to the value of I square and by a statistical test for heterogeneity of effect estimates in a meta-analysis.
(Imprecision assessment)
We will assess imprecision based on the total number of participants in all included studies.
(Meta-analysis)
Only when we will not find heterogeneity in RCT, qRCT, nonRCT, and crossover trials, TY will conduct a meta-analysis using RevMan 5. If we will find missing data, we will make contact with the author to obtain the data.
We will assess heterogeneity according to the value of I square in Forest plot and assess publication bias using Funnel plot.
We will conduct subgroup analyses:
i) restricting to randomized controlled parallel-group trials.
ii) restricting to people burdened with stress-inducing task or not.
iii) excluding trials whose sample sizes are predominantly large compared with the other trials.
2017 | Year | 07 | Month | 27 | Day |
2023 | Year | 01 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032511
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |